Xia, Zhongjun
Leng, Yun
Fang, Baijun
Liang, Yang
Li, Wei
Fu, Chengcheng
Yang, Linhua
Ke, Xiaoyan
Jiang, Hua
Weng, Jianyu
Liu, Li
Zhao, Yaozhong
Zhang, Xuejun
Huang, Zhongxia
Liu, Aichun
Shi, Qingzhi
Gao, Yuhuan
Chen, Xiequn
Pan, Ling
Cai, Zhen
Wang, Zhao
Wang, Yafei
Fan, Yaqun
Hou, Ming
Ma, Yigai
Hu, Jianda
Liu, Jing
Zhou, Jianfeng
Zhang, Xiaohong
Meng, Haitao
Lu, Xuzhang
Li, Fei
Ren, Hanyun
Huang, Bintao
Shao, Zonghong
Zhou, Hebing
Hu, Yu
Yang, Shifang
Zheng, Xiangjun
Wei, Peng
Pang, Hongyan
Yu, Wei
Liu, Yuzhang
Gao, Sujun
Yan, Lingzhi
Ma, Yanping
Jing, Hongmei
Du, Juan
Ling, Wei
Zhang, Jingyi
Sui, Weiwei
Wang, Fuxu
Li, Xin
Chen, Wenming
Funding for this research was provided by:
Beijing Sunbio Biotech. Co., Ltd., a wholly-owned subsidiary of Wuhan Hiteck Biological Pharma Co., Ltd.
National Major Science and Technology Projects of China (2018ZX09733003)
Article History
Received: 12 April 2023
Accepted: 8 October 2023
First Online: 14 October 2023
Declarations
:
: The trial protocol was approved by the independent ethics committees of Beijing Chao-Yang Hospital Capital Medical University. The trial was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent before enrolment.
: Not applicable.
: SY, XZ, PW, HP and WY are employees of Beijing Sunbio Biotech Co. Ltd. The other authors declare that they have no competing interests.